Kezar Life Sciences Stock
-
Your prediction
Kezar Life Sciences Stock
Pros and Cons of Kezar Life Sciences in the next few years
Pros
Cons
Performance of Kezar Life Sciences vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Kezar Life Sciences | - | - | - | - | - | - | - |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon examining the financial statements of Kezar Life Sciences (KZR), a company operating in the Biotechnology & Medical Research industry, it's clear that the firm is going through a phase of consistent investment in research and development. The company has shown growth in assets and has managed to secure financing to fund its operations. However, there is considerable concern arising from its lack of revenue and growing net losses.
Growing Assets: The total assets for the company have consistently increased over the past three years (2020-2022), amounting to $151,842,000 in 2020 and reaching $299,568,000 by 2022. This growth in assets may indicate that Kezar Life Sciences is making strategic investments to advance its operations and research.
Increasing Investment in Research and Development: Kezar Life Sciences has been making significant investments in R&D, with expenditures rising from $30,981,000 in 2020 to $51,009,000 in 2022. This growing investment in research and development could signal the company's dedication to developing innovative therapies and treatments, which is crucial in the Biotechnology & Medical Research Industry.
Comments
